No Data
No Data
Individual Investors Are Jiangsu Recbio Technology Co., Ltd.'s (HKG:2179) Biggest Owners and Were Rewarded After Market Cap Rose by HK$489m Last Week
Gelonghui announcement highlights (Hong Kong stocks) | SUNNY OPTICAL (02382.HK) earnings surprise: It is expected that the annual net profit will increase significantly by 140% to 150%.
【Today's Focus】SUNNY OPTICAL (02382.HK) profit warning: expected annual net profit to increase significantly by 140% to 150%. SUNNY OPTICAL (02382.HK) announced that the group anticipates a net profit attributable to Shareholders of approximately RMB 2.6386 billion to RMB 2.7485 billion for the year ending December 31, 2024, an increase of approximately 140.0% to 150.0% compared to around RMB 1.0994 billion for the year ended December 31, 2023. The Board of Directors believes that the expected increase is mainly due to the following reasons: 1. The recovery of the Smart Phone market.
Express News | Jiangsu Recbio Technology - Acceptance of Application for Clinical Trial of Adjuvanted Recombinant Hpv 9-Valent Vaccine REC604C by Nmpa China
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
During the day, the stock price rose nearly 10% against the market trend. Can Reikang Bio-B (02179) break free from the liquidity trap in this critical year for commercialization?
In a context where the Sector is performing relatively weakly, Ruike Bio, which had been trading sideways for nearly two months, suddenly surged against the trend during trading due to the bullish news of the company receiving a 0.8 billion yuan private placement and the recent completion of Phase III clinical study enrollment for its self-developed adjuvant recombinant shingles vaccine REC610.
Reikou Bio-B (02179.HK) has completed the enrollment for the Phase III clinical trial of the new adjuvant recombinant shingles vaccine REC610.
On January 2, Gelonghui reported that esoteric Biotechnology-B (02179.HK) announced that the phase III clinical study of its independently developed new adjuvant recombinant shingles vaccine REC610 has successfully completed the enrollment of all subjects. This clinical study uses a randomized, double-blind, placebo-controlled design aimed at evaluating the protective efficacy, safety, and immunogenicity of the REC610 vaccine in healthy subjects aged 40 and above. A total of 24,640 subjects have been recruited across 18 research centers in Yunnan, Henan, and Shanxi Provinces. Shingles is a common disease caused by a latent viral infection, which can lead to complications for patients.
whqqq : Will they fall after a pandemic?
Spinee OP whqqq : It's hard to say![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
whqqq Spinee OP : But it can still be held for a short time, right?![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)